Alright degenerates, put down the weekly options for 5 minutes and hear me out.
AbCellera Biologics (ABCL) — Canadian biotech, antibody discovery platform, and the company about to drop a Phase 2 readout that management literally called "by far the most important data readout in 2026." When management says that, you listen.
THE PLAY:
ABCL-635 is a treatment for postmenopausal vasomotor symptoms (hot flashes). ~$6B U.S. market. Phase 1 already showed:
- ✅ No liver toxicity (huge, this kills most drugs) * ✅ ~24-day half-life = once-monthly dosing (patients actually stay on it) * ✅ Strong biomarker suppression
Phase 2 topline readout expected Q3 2026. That's the binary event. Clean data = stock rips. Miss = it gets destroyed. Classic biotech lottery ticket — except this one has actual fundamentals backing it.
WHY THIS ISN'T JUST ANOTHER BIOTECH GAMBLE:
- $655M total liquidity. $530M cash + $125M committed government funding * Burning ~$30M/quarter net * That's 4-5+ years of runway without dilution * They. Do. Not. Need. To. Raise.
You know how most clinical-stage biotechs dilute you into oblivion while you hold the bag? Not here. This is genuinely rare.
Revenue nearly doubled YoY ($4.2M → $8.3M Q1). Still losing money obviously, but R&D spend is up because they're actually building a pipeline, not just one drug.
PIPELINE BEYOND THE BINARY:
- ABCL-575 Phase 1 data Q4 2026 (autoimmune) * ABCL-688 and ABCL-386 targeting clinical entry by 2027 * At least one new development candidate dropping in 2026
This isn't a one-trick pony. If 635 hits, the rest of the pipeline gets re-rated too.
THE RISK (yes I'm including this, I've grown):
Phase 2 miss takes the stock down hard. This is a binary event. If you can't stomach a 40-50% drawdown, size accordingly. Don't put in money you need for rent. Actually don't listen to me at all I'm just some guy.
TLDR: ABCL has $655M cash, 4-5 year runway, no dilution risk, and a Phase 2 hot flash drug readout in Q3 that could re-rate the entire company. Management called it their most important catalyst ever. Stock is pricing in fear. I'm pricing in tendies.
Positions or ban:
This is not financial advice. I eat crayons for breakfast.